New research presented today at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting highlights a significant step toward developing a stem cell-based treatment for chronic spinal cord injury (SCI), a condition for which no effective restorative therapy currently exists.
Hideyuki Okano, M.D., Ph.D., Keio University, Japan, presented new preclinical efficacy data using clinical-grade gliogenic neural stem/progenitor cells (gNS/PCs) for chronic incomplete SCI, along with newly updated plans for a physician-initiated clinical trial targeting patient recruitment in 2027. The findings build on the successful completion of a world-first, first-in-human clinical study in patients with subacute SCI that demonstrated a promising safety profile.
We have already successfully completed a world-first, first-in-human clinical study targeting patients in the subacute phase, which demonstrated a promising safety profile. Our shift to the chronic phase is the next logical milestone, built upon that solid foundation. Since the cellular environment changes over time, we are evolving our strategy from just establishing safety to actively overcoming the stubborn, long-standing barriers of chronic paralysis."
Dr. Hideyuki Okano, ISSCR's president
The upcoming clinical trial will focus on patients with chronic, incomplete spinal cord injuries who retain inactive but demyelinated nerve fibers and lack sufficient endogenous cellular support, making them appropriate candidates for this remyelination-focused strategy.
"While previous approaches focused on transplanting 'neuron-generating' cells, chronic injuries present a different challenge: residual nerve fibers exist but have lost their protective insulation," said Okano. "Our unique strategy uses gliogenic cells (gNS/PCs), which are specifically tailored to generate the vital support cells-astrocytes and oligodendrocytes. Rather than trying to grow entirely new nerves, we are essentially 'repairing and rebooting' the existing wiring of the spinal cord."
In preclinical studies, the clinical-grade gNS/PCs efficiently differentiated into neurons, astrocytes, and oligodendrocytes in vitro and, following transplantation into chronic injury models, safely promoted behavioral recovery without tumor-like tissue formation while remodeling the injured microenvironment.
If confirmed in future clinical studies, the approach could represent a significant advance for people living with chronic spinal cord injury. The physician-initiated clinical trial is expected to begin recruiting patients in 2027, with the long-term goal of developing a safe, standardized therapy capable of restoring voluntary movement and autonomic function for chronic patients.
Facts Only
* Hideyuki Okano, M.D., Ph.D. from Keio University, Japan, presented data at the ISSCR 2026 Annual Meeting.
* The research involved using clinical-grade gliogenic neural stem/progenitor cells (gNS/PCs) for chronic incomplete SCI models.
* Previous studies demonstrated a promising safety profile in first-in-human trials for subacute SCI patients.
* The planned clinical trial will target patients with chronic, incomplete spinal cord injuries who retain inactive but demyelinated nerve fibers lacking endogenous cellular support.
* The strategy utilizes gliogenic cells (gNS/PCs) to generate astrocytes and oligodendrocytes, aiming to "repair and reboot" existing wiring rather than grow new nerves.
* Preclinical studies showed gNS/PCs differentiated into neurons, astrocytes, and oligodendrocytes in vitro.
* Transplantation into chronic injury models safely promoted behavioral recovery without tumor-like tissue formation.
* The physician-initiated clinical trial is planned to recruit patients starting in 2027.
Executive Summary
New preclinical data presented at the ISSCR 2026 Annual Meeting detail progress toward a stem cell-based treatment for chronic spinal cord injury (SCI). Hideyuki Okano presented efficacy data using clinical-grade gliogenic neural stem/progenitor cells (gNS/PCs) applied to chronic incomplete SCI. This research builds upon previous successful in-vivo studies demonstrating safety for subacute SCI patients, setting the stage for a transition to chronic injury models.
The proposed strategy focuses on using gNS/PCs to generate supportive cells—astrocytes and oligodendrocytes—rather than generating new neurons. Preclinical testing showed that these cells safely remodeled the injured microenvironment without tumor formation while promoting behavioral recovery in chronic injury models. A physician-initiated clinical trial targeting patients with chronic, incomplete SCI who have demyelinated nerve fibers is planned to begin patient recruitment in 2027.
Full Take
The transition from subacute safety studies to chronic treatment necessitates a critical re-evaluation of the intervention's targets, moving from establishing safety to overcoming long-standing biological barriers associated with chronic paralysis. The strategy shifts from neurogenesis to microenvironmental remodeling via gliogenic cells, which suggests an implicit recognition that the failure in chronic SCI is less about generating new tissue and more about managing the existing, dysfunctional cellular environment.
The concept of "repairing and rebooting" existing wiring implies a deep acceptance that the primary challenge in chronic injury lies in cellular support deficit and demyelination rather than wholesale nerve regeneration. This places an interesting tension between established methods focused on cell transplantation (neuron-generating cells) and this novel approach focused on supportive scaffolding. The move to physician-initiated trials emphasizes a necessary shift in clinical focus, recognizing that chronic conditions require tailored therapeutic approaches based on specific pathophysiology, moving away from generalized regenerative goals.
What constitutes "sufficient endogenous cellular support" and how is the risk of adverse remodeling managed when dealing with established scar tissue and chronic inflammation? Furthermore, if the mechanism relies on modulating astrocytes and oligodendrocytes, what are the long-term implications for autonomic function beyond voluntary movement? What parallels exist between successful microenvironmental scaffolding in acute injury models and the complex, protracted healing trajectory of chronic lesions?
Sentinel — Human
This text appears to be a human-authored summary or report focusing on scientific research, characterized by coherent argument and specific technical detail rather than synthetic pattern generation.